Skip to main content
S&P 5007,585.73-0.45%DOW52,093.11-0.63%NASDAQ25,981.57-0.78%BTC$75,900.00-1.51%ETH$2,404.54-3.20%GOLD$4,387.30+1.26%OIL$103.71-2.00%
Smart Investors Daily
SL

NASDAQ · SLS

SELLAS Life Sciences Group, Inc.

Healthcare · Biotechnology

$11.29

Down-$0.44 (-3.71%)

Updated Sep 16, 2026, 10:18 AM

SID Score

4.9/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
211.34M
P/E ratio
-7.53
Dividend yield
0.00%
52-week range
$1.39 – $15.88
Volume
5.24M
Avg. volume
4.07M

Price performance

SLS price history

1M range · 20 trading sessions · Daily adjusted prices

SLS closed at $11.29 after 20 trading sessions, down 13.82% for the selected period.

Last close
$11.29
Period change
-13.82%
Period low
$11.29
Period high
$15.46
Daily close
View OHLC price history
SLS OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 15, 2026$11.60$11.70$11.03$11.295.24M
Sep 14, 2026$10.91$12.28$10.784$11.72510.54M
Sep 11, 2026$13.55$13.74$11.38$11.54514.71M
Sep 10, 2026$13.66$13.825$13.37$13.494.83M
Sep 9, 2026$13.71$14.33$13.71$13.955.5M
Sep 8, 2026$13.77$14.37$13.32$13.966.06M
Sep 4, 2026$13.51$14.14$13.43$13.864.53M
Sep 3, 2026$14.06$14.5442$13.55$13.705.78M
Sep 2, 2026$13.27$14.33$13.23$14.166.24M
Sep 1, 2026$13.02$13.39$12.6401$13.225.91M
Aug 31, 2026$13.325$13.6693$12.9386$13.347.45M
Aug 28, 2026$14.77$14.79$13.15$13.219.83M
Aug 27, 2026$14.078$15.56$13.9157$15.2112.12M
Aug 26, 2026$13.815$13.915$13.41$13.734.59M
Aug 25, 2026$14.56$15.39$13.91$14.098.21M
Aug 24, 2026$15.475$15.48$13.91$14.3258.82M
Aug 21, 2026$13.69$15.67$13.26$15.4615.24M
Aug 20, 2026$13.84$14.4364$13.01$13.407.82M
Aug 19, 2026$13.46$14.29$13.00$13.859.12M
Aug 18, 2026$12.66$13.48$12.53$13.104.97M

Latest SLS news

The latest Smart Investors Daily articles mentioning SLS.

Stock researchCompany · Overview

SLS research

Overview

Company profile and research snapshot.

Company profile

SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$2.80
Implied upside
—
Analysts
—
SLS recent ratings
DateFirmRatingTarget
Jul 16, 2025Maxim GroupBuy—
Nov 22, 2023Cantor FitzgeraldOverweight—
Sep 7, 2023Cantor FitzgeraldOverweight—
Nov 15, 2022Alliance Global PartnersBuy—
Jun 28, 2022Cantor FitzgeraldOverweight—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 3, 2026

SELLAS Life Sciences Group (SLS) Lands 3 AACR Abstracts For SLS009 Pancreatic Cancer Data

SELLAS Life Sciences Group (NasdaqCM:SLS) will present new preclinical data on SLS009 in pancreatic ductal adenocarcinoma at the 2026 AACR Conference. Three abstracts on SLS009 have been accepted, focusing on its mechanism of action and activity in KRAS mutant pancreatic cancer models. The research is being carried out with a respected academic institution and adds detail on SLS009 within SELLAS Life Sciences Group's preclinical pipeline. Interest in SELLAS Life Sciences Group reflects a...

Yahoo · Sep 2, 2026

SELLAS Life Sciences to Present Preclinical Data on SLS009 in Pancreatic Ductal Adenocarcinoma at the 2026 AACR Conference on Pancreatic Cancer

- Three posters to highlight preclinical activity of SLS009 (tambiciclib) across patient-derived KRAS mutant organoid models of pancreatic cancer – - Studies conducted in collaboration with the University of Wisconsin School of Medicine and Public Health - NEW YORK, Sept. 02, 2026 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By